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P. Kno¨bl31Department of General and Vascular Surgery, Wilhelminenspital Vienna, 2Clinical Institute for Hygiene and
Medical Microbiology, Medical University of Vienna, and 3Department of Medicine, Medical University of
Vienna, Vienna, AustriaBackground. The aim of this study was to evaluate the current practice of peri and postoperative antithrombotic therapy in
vascular surgery in Austria and to compare this with the results of randomised prospective clinical trials.
Methods. A questionnaire assessing intra, postoperative and long-term antithrombotic treatment in 13 different surgical
procedures (three supra-aortic, three aorto-iliac reconstructions and seven inguinal and infra-inguinal arterial
reconstructions) was sent to all 22 institutions training vascular surgical fellows in Austria.
Results. Intraoperative antithrombotic therapy was quite consistently performed with unfractionated heparin (UFH) with
or without acetylsalicylic acid (ASA). Early and long-term postoperative therapy differed considerably. Most centres used
low molecular weight heparin (LMWH) for early postoperative therapy after vascular reconstructions, inO75% combined
with ASA and/or clopidogrel. Long-term therapy consisted of antiplatelet agents in all centres. Vascular grafts were
anticoagulated with UFH in 25% of the centres in the early postoperative period, the remaining institutions used LMWHG
antiplatelet agents. For long-term antithrombotic therapy cumarins were used in 75% of the centres, predominantly for
venous grafts. Distal prosthetic grafts were mainly treated with antiplatelet agents. Intraoperative antithrombotic therapy
was in accordance to present guidelines, postoperative antithrombotic therapy, however, differed considerably between the
participating institutions and the results of available controlled studies.
Conclusion. Optimal antithrombotic strategies during and after vascular surgery are still under debate, and current
practice often differs from available evidence. Vascular surgical societies should be encouraged to define recommendations on
antiplatelet therapy and anticoagulation for different vascular interventions.Keywords: Anticoagulation; Antiplatelet agents; Vascular surgery; Graft patency.Introduction
Antithrombotic therapy is a fundamental component
of vascular surgery and contributes significantly to the
early and late outcomes of vascular reconstructions.
The first anticoagulant substance used intraopera-
tively was unfractionated heparin (UFH),1 enabling
successful completion of vascular surgical procedures
that had previously been associated with high perio-
perative thrombosis rates. Nowadays, antithrombotic
therapy in conventional vascular surgery comprises
antiplatelet agents, vitamin K antagonists, thrombin
inhibitors, UFH and low molecular weight heparinsing author. Afshin Assadian, MD, Department of
Vascular Surgery, Wilhelminenspital Vienna, Mon-
7, A-1160 Vienna, Austria.
: afshin_assadian@yahoo.de
0516+ 06 $35.00/0 q 2005 Elsevier Ltd. All rights reser(LMWH). The intraoperative use of these drugs aims
to reduce or preclude thrombosis at the site of surgery
and thromboembolic events downstream. Postopera-
tively, the main aim of antithrombotic therapy is to
increase vascular reconstruction and bypass patency
rates. Furthermore, antiplatelet agents have been
shown to significantly reduce cardiovascular, cerebro-
vascular and peripheral vascular morbidity and
mortality.2–4
However, optimal anticoagulation and antiplatelet
strategies during and after vascular surgery are still
under debate. Although several good controlled
studies investigated antithrombotic therapies for
surgical interventions in arterial occlusive disease,
such therapies may vary with the type of surgery, the
use of grafts or stents, and the clinical situation of
patients. Therefore, stringent guidelines or even
recommendations are rare. The aim of this study wasEur J Vasc Endovasc Surg 29, 516–521 (2005)
doi:10.1016/j.ejvs.2005.01.021, available online at http://www.sciencedirect.com onved.
Use of Antithrombotic Drugs 517to evaluate the current practice of perioperative and
postoperative antithrombotic therapy in vascular
surgery in Austria for procedures of different vascular
regions, and compare it with the results of the existing
controlled studies.Methods
In March 2004, a questionnaire assessing antithrom-
botic strategies before, during and after vascular
surgery was sent to all 22 institutions training vascular
surgical fellows in Austria. These centres were
selected because of their great expertise in this field
and the highly standardised institutional guidelines,
which are mandatory for all members of such
institutions. Therefore, we assumed that the answers
to the questionnaire may best represent the current
state of applied evidence in antithrombotic therapy in
vascular surgery in most vascular surgical depart-
ments in Western Europe.
The questionnaire asked for general antithrombotic
strategies for ‘standard’ patients (without a coexisting
thromboembolic risk, stroke, bleeding tendency, the
need of individual therapy because of other reasons, or
multiple interventions in different vascular region); for
therapeutic regimens for pre and intraoperative antic-
oagulation, early postoperative antithrombotic
therapy (from the first day after surgery until
discharge from the hospital), and for modality and
duration of long-term outpatient antithrombotic
therapy. Antithrombotic strategies were assessed for
13 different surgical procedures (three supra aortic,
four aorto-iliac and inguinal reconstructions and six
types of infra-inguinal bypass surgery).Results
Of the 22 questionnaires, 16 were returned within 2
months (72%); institutions that did not respond or
decided not to participate were not contacted a second
time. Intraoperative antithrombotic therapy is shown
in Table 1, postoperative modalities on the ward in
Table 2, and outpatient anticoagulant practice is
shown in Table 3. The intraoperative anticoagulation
regimen was quite consistent within the responding
institutions and the type of surgery. UFH was given in
all institutions as an intravenous bolus prior to arterial
clamping. Ten of the responding institutions used 5000
international units (IU) of UFH, one used 30 IU UFH
per kg body weight, three used 100 IU UFH per kg
body weight, one unit administered 7000–9000 IUUFH and one institution routinely used 10,000 IU
UFH for all surgical procedures.Carotid, vertebral and subclavian artery reconstructions
For intraoperative anticoagulation during carotid
endarterectomy, vertebral artery surgery and subcla-
vian artery surgery, nine institutions (56%) used UFH
alone, and in seven centres (44%) UFH was combined
with ASA and/or clopidogrel. For anticoagulation
during the early postoperative period (patients in
hospital), LMWH was used in 15 centres (94%) in a
prophylactic dose (40 mg enoxaparin once daily
subcutaneously), most often combined with antiplate-
let drugs. Antiplatelet agents were the preferred
treatment for outpatients after supra-aortic artery
reconstruction and consisted of ASA alone in 14
institutions (87.5%) and of lifelong clopidogrel and
ASA in two institutions (12.5%).Aorto-iliac and inguinal reconstructions
For antithrombotic therapy during surgical interven-
tions of aorto-iliac disease 14 (87.5%) of all respon-
dents used UHF alone, two (12.5%) respondents used
ASA and UFH. Early postoperative therapy consisted
of LMWH in all institutions, but was combined with
antiplatelet drugs in 11 centres (69%). In one centre
(6%) UFHCASA were given after inguinal endarter-
ectomy. Low dose LMWH (40 mg enoxaparin once
daily subcutaneously) was given in 12 responding
institutions, the other centres used half of the usual
therapeutic dose (1 mg enoxaparin/kg body weight),
administered once daily. The outpatient treatment
after aorto-iliac surgery consisted of ASA in most
centres. Only one institution treated patients with a
combination of ASA and clopidogrel, and one
refrained from any long-term antiaggregatory treat-
ment after surgery for abdominal aortic aneurysm or
aorto-iliac occlusive disease.Infrainguinal bypass surgery
UFH was used by all centres for intraoperative
anticoagulation in all inguinal and infra-inguinal
vascular surgical interventions. Three centres (19%)
combined UFH with ASA during all kinds of infra-
inguinal bypass surgery. Early postoperative antic-
oagulation varied considerably: for saphenous vein
bypass grafts to popliteal (above and below knee) and
crural arteries, a minority of centres used UFH alone
(four institutions, 25%). UFH was administered as aEur J Vasc Endovasc Surg Vol 29, May 2005
Table 1. Intraoperative anticoagulation during vascular surgery
UFH UFHCASA UFHCASAC
C
UFHCC
Supra-aortic surgery
Carotid endarterectomy, vertebral artery surgery,
subclavia transposition/bypass
9 5 1 1
Aorto-iliac reconstructions
Infra renal aortic aneurysm 14 2 0 0
Aorto-iliac occlusive disease 14 2 0 0
Common and external iliac occlusion 14 2 0 0
Inguinal endarterectomyGpatch 13 3 0 0
Infrainguinal bypass grafting
Venous grafts
Above knee femoropopliteal bypass, below knee
femoropopliteal bypass, crural bypass
13 3 0 0
Prosthetic grafts
Above knee femoropopliteal bypass (PTFE/
dacron), below knee femoropopliteal bypass
(PTFE), crural bypass (PTFE)
13 3 0 0
Results from the 16 responses to a survey of anticoagulation practice during vascular surgery in Austria. UFH, unfractionated heparin; ASA,
acetylsalicylic acid; C, clopidogrel; PTFE, polytetrafluoroethylene.
A. Assadian et al.518continuous intravenous infusion, aiming at an aPTT
ratio of 2–2.5. Fourteen centres (88%) used LMWH,
about half of them in combination with antiaggrega-
tory agents. Prosthetic grafts below the knee were
anticoagulated with UFH alone in four centres (25%).
Most other centres used LMWH for all kinds of
prosthetic bypasses, with a variable rate of additional
antiplatelet therapy. LMWHwas administered in eight
centres (50%) in a prophylactic dose (40 mg enoxa-
parin once daily subcutaneously), the other half ofTable 2. Early postoperative anticoagulation after vascular surgery
ASA UFH UFHCASA
Supra-aortic surgery
Carotid endarterectomy,
vertebral artery surgery,
subclavia transposition/
bypass
1 0 0
Aorto-iliac reconstructions
Infra renal aortic aneurysm 0 0 0
Aorto-iliac occlusive disease 0 0 0
Common and external iliac
occlusion
0 0 0
Inguinal endarterectomyG
patch
0 0 1
Infrainguinal bypass grafting
Venous grafts
Above knee femoropopliteal
bypass
0 2 0
Below knee femoropopliteal
bypass
0 3 0
Crural bypass (vein) 0 4 0
Prosthetic grafts
Above knee femoropopliteal
bypass (PTFE/dacron)
0 2 0
Below knee femoropopliteal
bypass (prosthetic)
2 4 0
Crural bypass (PTFE) 1 4 0
Results from the 16 responses to a survey of anticoagulation practice d
unfractionated heparin; LMWH, low molecular weight heparin; C, clo
Eur J Vasc Endovasc Surg Vol 29, May 2005respondents used a full anticoagulation dose. Long-
term outpatient treatment of saphenous vein bypass
grafts consisted, depending on the length of bypass,
either of vitamin K antagonists alone (8–11 centres; 50–
69%) or ASA alone 4–8 centres (25–50%). Only in one
centre ASAwas combined with clopidogrel. The target
INR for patients on vitamin K antagonists was 3–3.5. In
contrast, prosthetic bypasses above the knee were
treated predominantly with ASA and/or clopidogrel
(12 centres; 75%). For below knee prosthetic bypasses,LMWH LMWHC
ASA
LMWHCASACC
3 10 2
5 10 1
5 10 1
5 10 1
4 10 1
5 8 1
7 6 0
6 6 0
4 8 2
6 3 1
5 5 1
uring vascular surgery in Austria. ASA, acetylsalicylic acid; UFH,
pidogrel; PTFE, polytetrafluoroethylene.
Table 3. Postoperative outpatient anticoagulation after vascular surgery
ASA C ASACC VKA VKACASA NIL
Supra-aortic surgery
Carotid endarterectomy, vertebral
artery surgery, subclavia transposi-
tion/bypass
14 0 2 0 0 0
Aorto-iliac reconstructions
Infra renal aortic aneurysm 14 0 1 0 0 1
Aorto-iliac occlusive disease 14 0 1 0 0 1
Common and external iliac occlu-
sion
15 0 1 0 0 0
Inguinal endarterectomyGpatch 15 0 1 0 0 0
Infrainguinal bypass grafting
Venous grafts
Above knee femoropopliteal bypass 8 0 0 8 0 0
Below knee femoropopliteal bypass 5 0 0 11 0 0
Crural bypass 4 0 1 11 0 0
Prosthetic grafts
Above knee femoropopliteal bypass
(PTFE/dacron)
10 0 2 3 1 0
Below knee femoropopliteal bypass
(prosthetic)
7 0 1 7 1 0
Crural bypass (PTFE) 3 1 0 8 4 0
Results from the 16 responses to a survey of anticoagulation practice during vascular surgery in Austria. ASA, acetylsalicylic acid; C,
clopidogrel; VKA, vitamin K antagonists; nil, no anticoagulation at all; PTFE, polytetrafluoroethylene.
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(8–12 centres; 50–75%). The target INR for patients on
vitamin K antagonists was 3–3.5.Discussion
The present survey was conducted in institutions
training vascular surgical fellows in Austria. Due to
the structure of such departments in Austria and their
function as opinion leaders for vascular surgeons in
other institutions, treatment policies should best
reflect the current state of applied evidence in
antithrombotic therapy in Austria and Western
Europe. The aim of the study was to asses antithrom-
botic practice for standard patients. Patients with
coexisting conditions requiring individual treatment
different from these standards were excluded and are
not addressed in the current survey. In the last decade,
several randomised, controlled studies for intraopera-
tive and postoperative anticoagulation for arterial
reconstructions were conducted and published. Also,
large studies with antiplatelet agents for patients with
symptomatic atherosclerosis or at risk of ischaemic
events, predominantly in the coronary arteries, but
also for stroke and peripheral limb ischaemia were
published. Low dose ASA has been shown to reduce
the risk of occlusive events in all vascular regions.2,5
Long-term use of clopidogrel compared to ASA in
patients with atherosclerotic vascular disease has been
demonstrated to be more effective in reducing the
combined risk of myocardial infarction, ischaemicstroke and vascular death.3 However, the absolute risk
reduction rate was only 0.5%, indicating that 200
patients need to be treated in order to prevent one
ischaemic episode. A combination of clopidogrel and
ASA further reduced the risk of recurrent ischaemic
events; however, the risk of major bleeding was
increased in patients receiving a combination of
these drugs.4
The data of this survey demonstrate that intrao-
perative anticoagulation is the least controversial
strategy for anticoagulation during vascular surgery.
For aorto-iliac disease, inguinal and infra-inguinal
revascularization, there is no evidence of the benefit of
adjuvant antiplatelet therapy. Therefore, UFH alone is
the most commonly applied modality of intraopera-
tive anticoagulation. In carotid artery surgery, initial
reports suggested that intraoperative anticoagulation
with heparin as well as high dose ASA (600–1200 mg)
were associated with a lower risk of perioperative
stroke.6 A large prospective trial, however, has clearly
demonstrated that low dose ASA preoperatively was
associated with less perioperative neurological events
compared to a high dose regimen.7 A recent random-
ized trial of ASA and placebo versus ASA and
clopidogrel preoperatively reports a reduction of
postoperative emboli measured by trans-cranial Dop-
pler.8 Yet, in the clopidogrel group, haemostasis was
significantly prolonged, measured by an increase of
time from flow restoration of the internal carotid artery
to completion of skin closure.
More recently, a dedicated trial for secondary
prevention in patients with ischaemic neurologicalEur J Vasc Endovasc Surg Vol 29, May 2005
A. Assadian et al.520deficit comparing clopidogrel andASAwith clopidogrel
alone was published.9 The results of MATCH suggest,
that dual therapy does confer a risk reduction regarding
the endpoints ischaemic stroke, myocardial infarction,
vascular death or rehospitalisation for acute ischaemia.
However, reduction in risk was outweighed by life
threatening or major bleeding episodes. Nevertheless,
the results of the study have evoked some com-
ments,10,11 indicating caution in banning dual therapy
from the list of treatment options for secondary pre-
vention of stroke and recommending a more cautious
utilization until further studies are undertaken.11
For vertebral and subclavian artery surgery, no
trials evaluating the benefit of anticoagulation during
surgery are published, however, we suggest that
similar regimens to those for carotid endarterectomy
are appropriate.
LMWH is widely accepted for prophylaxis of
postoperative venous thromboembolism. It has been
proven as equally effective and safer compared to
UFH.12 For most interventions, except infrainguinal
bypass surgery, LMWH was administered at the dose
used for prophylaxis of venous thromboembolism. For
infrainguinal bypass-surgery, LMWH was adminis-
tered in eight centres in a prophylactic dose, the other
half of respondents used a full anticoagulation dose.
For the most distal bypasses, a continuous infusion of
UFH was used by a quarter of the responding
institutions. The evidence for this therapeutic modality
is not overwhelming. One prospective randomised trial
including 201 patients concluded LMWH to be as safe
but more effective than UFH for the prevention of graft
thrombosis.13 However, both substances were adminis-
tered subcutaneously. Therefore, these results are not
entirely comparable to an intravenous administration,
as the bio-availability ofUFH is inferior to LMWHwhen
administered subcutaneously.
The area showing most discrepancy in postopera-
tive out patient treatment is infra-inguinal bypass
surgery. Studies comparing oral anticoagulation with
vitamin K antagonists versus placebo14 and antiplate-
let agents versus placebo15 clearly demonstrate the
need for adjuvant antithrombotic therapy after bypass
surgery. The role of anticoagulation and platelet
inhibitors for different bypass materials after infra-
inguinal surgery is well documented by several
prospective randomised trials and meta-analyses.16–21
In preventing prosthetic infra-inguinal bypass graft
occlusions, low dose ASA is superior to vitamin K
antagonists. Oral anticoagulation, on the other hand,
does improve long-term patency rates for infra-
inguinal venous bypass grafts compared to ASA.
These recommendations are valid for above as well
as below knee bypasses. The suggested optimal oralEur J Vasc Endovasc Surg Vol 29, May 2005anticoagulation intensity to prevent secondary ischae-
mic and hemorrhagic events is an international
normalized ratio (INR) of 3.0–4.0.22
In our survey, many long-term anticoagulation
regimens are not in keeping with recommended
treatment strategies. For above knee venous femoro-
popliteal bypasses, 50% of all respondents use ASA
alone and, therefore, do not comply with level I
evidence. This therapeutic regimen may lead to early
graft occlusion compared to vitamin K antagonists for
venous bypasses. Moreover, 50% of all respondents
routinely use vitamin K antagonists for prosthetic
below knee femoro-popliteal bypasses. This may not
only lead to increased incidences of early bypass
failure compared to antiplatelet therapy in this patient
group, but also to the possibility of 23 major bleeding
episodes per 1000 patients annually.16 Furthermore,
only about 50% of INR readings are in the desired
range, even under study conditions in dedicated
anticoagulant clinics.22 Therefore, half of the patients
with prosthetic grafts are not optimally treated and at
an increased risk of bleeding complications, and half
of the patients with venous grafts are at increased risk
of bypass occlusion and hence limb ischaemia.
Optimal antithrombotic strategies during and after
vascular surgery are still under debate. They vary with
the type of surgery, the use of grafts, and the clinical
situation of patients. Obviously, the preference of
antithrombotic therapies does vary internationally
due to the presence or absence of dedicated antic-
oagulation clinics and also financial implications. This
applies specially to clopidogrel, a well tolerated drug
with minor superior beneficial effect compared to
ASA. The most striking inconsistency for long-term
postoperative anticoagulation is after infra-inguinal
bypass surgery. Even though randomised controlled
trials do exist for this specific issue, more than half of
the replying institutions do not comply in some point
with the evidence gained in these trials. However,
clinical decision making of adequate antithrombotic
therapy in peripheral arterial disease is demanding.
This is also reflected by the organisation of the
Peripheral Arterial Diseases Antiplatelet Consensus
Group, who recently published guidelines for the use
of antiplatelet agents.23 In this light, Vascular Surgical
Societies should be encouraged to define recommen-
dations on antiplatelet therapy and anticoagulation for
different vascular interventions.References
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